Lantern Pharma (LTRN) Net Income (2020 - 2026)
Lantern Pharma's (LTRN) quarterly Net Income came in at -$3.4 million in Q1 2026, up 27.68% YoY from -$2.6 million in Q1 2025, and up 18.93% on a QoQ basis from -$4.2 million in Q4 2025.
Lantern Pharma (LTRN) Net Income (2020 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 7 years of Net Income data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Net Income rose 27.68% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.9 million (up 14.47% YoY) and the FY2025 annual result came in at -$39.3 million, changed 0.12% from the prior year.
- Net Income advanced to -$3.4 million in Q1 2026, from -$4.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.8 million in Q3 2022 to a low of -$6.1 million in Q4 2022.
- A 5-year average of -$4.8 million and a median of -$4.6 million in 2023 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 31.61% in 2022, down 81.69% in 2022.
- Tracing LTRN's Net Income over 5 years: stood at -$6.1 million in 2022, then advanced by 24.7% to -$4.6 million in 2023, then declined by 25.01% to -$5.8 million in 2024, then climbed by 27.91% to -$4.2 million in 2025, then rose by 18.93% to -$3.4 million in 2026.
- The last three Net Income figures came in at -$3.4 million (Q1 2026), -$4.2 million (Q4 2025), and -$5.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | -3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.38 Mn |
| Dec 31, 2025 | -4.17 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | -4.54 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -5.01 Mn |
| Jun 30, 2024 | -5.45 Mn |
| Mar 31, 2024 | -5.58 Mn |
| Dec 31, 2023 | -4.63 Mn |
| Sep 30, 2023 | -4.09 Mn |
| Jun 30, 2023 | -5.94 Mn |
| Mar 31, 2023 | -4.19 Mn |
| Dec 31, 2022 | -6.15 Mn |
| Sep 30, 2022 | -2.82 Mn |
| Jun 30, 2022 | -4.51 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -4.13 Mn |
| Jun 30, 2021 | -2.48 Mn |